Seeking Alpha

StemCells (STEM +2%) moves higher after announcing a conference call to discuss results from its...

StemCells (STEM +2%) moves higher after announcing a conference call to discuss results from its Phase I clinical trial of HuCNS-SC - purified human neural stem cells used as a potential treatment for PMD, a rare hypo-myelination disorder in children.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector